The protracted legal conflict surrounding glyphosate has taken a significant turn for Bayer, with the company now receiving high-level backing from the U.S. government. The Trump administration has formally aligned itself with the chemical giant, aiming to push for a pivotal Supreme Court ruling. This political support emerges even as a separate challenge builds against the firm’s proposed multi-billion dollar settlement plan.
A Critical Supreme Court Hearing Approaches
At the heart of the legal strategy is the case of Durnell v. Monsanto. Bayer’s defense hinges on the argument that federal law, specifically the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), preempts more stringent labeling requirements imposed by individual U.S. states. The company contends that since the Environmental Protection Agency (EPA) approved the product label without a cancer warning, it cannot be held liable at the state level for the absence of such a warning.
In a major development, the U.S. Department of Justice officially endorsed this legal position on March 3, 2026. Market observers view this intervention as a crucial signal ahead of the upcoming Supreme Court proceedings. Oral arguments before the nation’s highest court are scheduled for April 27, 2026. A ruling in Bayer’s favor could potentially undermine the legal foundation for thousands of pending lawsuits.
Settlement Plan Faces Legal Hurdles
Concurrently, Bayer is attempting to resolve its legacy liabilities through a massive settlement valued between $7.25 and $7.3 billion. This strategy, however, is encountering resistance. More than a dozen law firms, representing approximately 20,000 claimants, have filed objections to the expedited approval process for the deal. They are requesting an additional 60-day review period, citing concerns over whether all affected parties are being adequately represented.
The scale of the litigation remains immense. Bayer still faces between 60,000 and 65,000 open claims in the United States. The company has already paid out roughly $11 billion in compensation, while its provisions for ongoing litigation most recently stood at €11.8 billion.
Should investors sell immediately? Or is it worth buying Bayer PK?
Political Moves Frame Herbicide as National Priority
Support from Washington extends beyond the courtroom. A current draft of the U.S. Farm Bill proposes uniform labeling rules, which would bolster Bayer’s legal standing. Furthermore, President Trump has invoked the Defense Production Act to classify glyphosate production as a matter of national security, elevating domestic herbicide manufacturing to an issue of strategic importance.
These political maneuvers come at a critical juncture. Reports suggest that the financial strain of the litigation had led Bayer to consider exiting the herbicide market altogether. Operationally, glyphosate remains vital, contributing approximately 12% to the annual revenue of its Crop Science division, which totals around $30 billion.
Investor sentiment remains tense. The stock, having declined roughly 12% over the past week, is considered technically oversold with a Relative Strength Index (RSI) reading of 16.3.
The coming weeks hold key dates: the Supreme Court hearing on April 27, 2026, and a preliminary hearing concerning the proposed multi-billion dollar settlement set for May 4, 2026.
Ad
Bayer PK Stock: Buy or Sell?! New Bayer PK Analysis from March 4 delivers the answer:
The latest Bayer PK figures speak for themselves: Urgent action needed for Bayer PK investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 4.
Bayer PK: Buy or sell? Read more here...
